Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Solid Tumors

Active, not recruiting

2

Start Date 08/26/2019

Age of Trial (yrs) 5.2

Gleevec-resistant

SDH-directed

Block related tumor signal paths

GIST not specified. GIST patient enrollment unknown.

NCI-2019-01365 NCI-2019-01365 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) NCI10220 10220 ( Other Identifier: University of Texas MD Anderson Cancer Center LAO ) 10220 ( Other Identifier: CTEP ) UM1CA186688 ( U.S. NIH Grant/Contract )

National Cancer Institute (NCI)

Principal Investigator: Vivek Subbiah University of Texas MD Anderson Cancer Center LAO

Oral

Patients must have histologically confirmed malignancy that is metastatic or unresectable

Patient must have histopathologic confirmation of advanced solid tumor with NF1 mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors (molecular profiling performed in any Clinical Laboratory Improvement Act [CLIA] certified lab [including tumor and circulating cell-free (cf)DNA], e.g. Caris, FoundationOne, FoundationAct, Oncomine, Guardant etc.)

NOTE: For all cohorts annotation for actionability will be performed by the PRECISION ONCOLOGY DECISION SUPPORT (PODS) TEAM SHEIKH KHALIFA BIN ZAYED AL NAHYAN INSTITUTE FOR PERSONALIZED CANCER THERAPY (IPCT) THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 6565 MD ANDERSON BLVD, HOUSTON, TX 77030

Patient must have no standard therapies available
Patients for NF1 mutant MPNST and NF1 mutant non-MPNST cohorts must be >= 40 kg